Converting weak binders into infinite binders

被引:28
作者
Corneillie, TM [1 ]
Whetstone, PA [1 ]
Lee, KC [1 ]
Wong, JP [1 ]
Meares, CF [1 ]
机构
[1] Univ Calif Davis, Dept Chem, Davis, CA 95616 USA
关键词
D O I
10.1021/bc049825e
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Monoclonal antibody 2D 12.5 binds DOTA chelates of all the rare earths with K-d approximate to10(-8) M, making it useful for the capture of probe molecules with a variety of properties. To make 2D12.5 even more useful for biological applications, we have engineered a single cysteine residue at position 54 of the heavy chain, a site proximal to the protein's binding site, so that weakly electrophilic metal complexes of (S)-2-(4-acrylamidobenzyl)-DOTA (AABD) may bind and form permanent linkages. At 37 degreesC, pH 7.5, all of the rare earth-AABD complexes bind permanently to the 2D12.5 G54C mutant within 5 min, in yields that correlate with their relative binding affinities. Surprisingly, indium-AABD also binds permanently in >50% yield within 5 min, despite the fact that changing the metal to indium reduces the affinity approximate to100x; even copper-AABD, which has approximate to10 000x lower binding affinity than the rare earths, binds permanently in > 70% yield within 2 h. However, acrylamido compounds with no measurable affinity do not bind permanently. The important practical implication is that the G54C mutant of 2D12.5 may be used for applications that include not only the rare earths, but also an unexpected range of other elements as well. This infinite binding system can exhibit selective and permanent attachment with a remarkable range of structurally related ligands, albeit at slower rates as affinities decrease.
引用
收藏
页码:1389 / 1391
页数:3
相关论文
共 15 条
[1]   SYNTHESIS, CHARACTERIZATION, AND CRYSTAL-STRUCTURES OF M(DO3A) (M = FE, GD) AND NA[M(DOTA)] (M = FE, Y, GD) [J].
CHANG, CA ;
FRANCESCONI, LC ;
MALLEY, MF ;
KUMAR, K ;
GOUGOUTAS, JZ ;
TWEEDLE, MF ;
LEE, DW ;
WILSON, LJ .
INORGANIC CHEMISTRY, 1993, 32 (16) :3501-3508
[2]   Reactivity of functional groups on the protein surface: Development of epoxide probes for protein labeling [J].
Chen, G ;
Heim, A ;
Riether, D ;
Yee, D ;
Milgrom, Y ;
Gawinowicz, MA ;
Sames, D .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2003, 125 (27) :8130-8133
[3]   Electrophilic chelating agents for irreversible binding of metal chelates to engineered antibodies [J].
Chmura, AJ ;
Schmidt, BD ;
Corson, DT ;
Traviglia, SL ;
Meares, CF .
JOURNAL OF CONTROLLED RELEASE, 2002, 78 (1-3) :249-258
[4]   Antibodies with infinite affinity [J].
Chmura, AJ ;
Orton, MS ;
Meares, CF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (15) :8480-8484
[5]   A rare earth-DOTA-binding antibody: Probe properties and binding affinity across the lanthanide series [J].
Corneillie, TM ;
Whetstone, PA ;
Fisher, AJ ;
Meares, CF .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2003, 125 (12) :3436-3437
[6]   Irreversible engineering of the multielement-binding antibody 2D12.5 and its complementary ligands [J].
Corneillie, TM ;
Lee, KC ;
Whetstone, PA ;
Wong, JP ;
Meares, CF .
BIOCONJUGATE CHEMISTRY, 2004, 15 (06) :1392-1402
[7]   Crystal structures of two complexes of the rare-earth-DOTA-binding antibody 2D12.5: Ligand generality from a chiral system [J].
Corneillie, TM ;
Fisher, AJ ;
Meares, CF .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2003, 125 (49) :15039-15048
[8]   Conformational characterization of lanthanide(III)-DOTA complexes by ab initio investigation in vacuo and in aqueous solution [J].
Cosentino, U ;
Villa, A ;
Pitea, D ;
Moro, G ;
Barone, V ;
Maiocchi, A .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2002, 124 (17) :4901-4909
[9]  
GOODWIN DA, 1994, CANCER RES, V54, P5937
[10]   Developing inhibitors of the epidermal growth factor receptor for cancer treatment [J].
Grünwald, V ;
Hidalgo, M .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (12) :851-867